Profile data is unavailable for this security.
About the company
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-151.40m
- Incorporated2021
- Employees52.00
- LocationArriVent BioPharma Inc18 Campus Blvd., Suite 100NEWTOWN SQUARE 19073-3269United StatesUSA
- Phone+1 (240) 780-6356
- Fax+1 (302) 636-5454
- Websitehttps://arrivent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annexon Inc | 0.00 | -208.88m | 828.25m | 99.00 | -- | 4.09 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Xencor Inc | 167.36m | -138.75m | 829.08m | 250.00 | -- | 1.32 | -- | 4.95 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 841.45m | 55.00 | -- | 2.08 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 855.88m | -- | 53.61 | 1.33 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 865.43m | 62.00 | -- | 2.68 | -- | 146.26 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Arvinas Inc | 312.30m | -58.50m | 865.74m | 430.00 | -- | 1.69 | -- | 2.77 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 902.41m | 52.00 | -- | 2.93 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 940.68m | 50.00 | -- | 3.23 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 945.90m | 596.00 | -- | 0.9801 | -- | 26.78 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 960.70m | 119.00 | 14.08 | 8.72 | 32.79 | 8.45 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 961.33m | -- | -- | -- | -- | 172.90 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 972.96m | 14.00 | -- | 23.56 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| Geron Corp | 183.40m | -79.99m | 976.68m | 229.00 | -- | 3.93 | -- | 5.33 | -0.1202 | -0.1202 | 0.2754 | 0.3896 | 0.3623 | 0.073 | 5.79 | 800,886.40 | -15.80 | -47.39 | -20.34 | -60.65 | 97.70 | -- | -43.61 | -871.15 | 4.87 | -4.25 | 0.4999 | -- | 32,386.92 | 178.45 | 5.19 | -- | 10.49 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 991.45m | 162.00 | -- | 6.71 | -- | 6.94 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
Data as of Feb 06 2026. Currency figures normalised to ArriVent BioPharma Inc's reporting currency: US Dollar USD
56.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 30 Sep 2025 | 4.48m | 10.86% |
| Infinitum Asset Management LLCas of 30 Sep 2025 | 3.87m | 9.37% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 3.70m | 8.97% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.41m | 8.25% |
| Octagon Capital Advisors LPas of 30 Sep 2025 | 1.97m | 4.78% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.85m | 4.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.63m | 3.94% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.03m | 2.49% |
| Geode Capital Management LLCas of 30 Sep 2025 | 716.29k | 1.74% |
| Pleasant Lake Partners LLCas of 30 Sep 2025 | 619.85k | 1.50% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
